The validity of this AITL model and the relevance of NIK inhibition for this disease was confirmed by a clear effect of the NIK inhibitor on the reduced survival of CD4+ Tfh cells and B cells in human AITL biopsies ex vivo. The gene discussed is CD4; the disease is angioimmunoblastic T-cell lymphoma.